{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:31:26Z","timestamp":1793633486065,"version":"4.5.1"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/ Z505274\/1"],"award-info":[{"award-number":["MR\/ Z505274\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lanepe.2026.101850","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T19:23:51Z","timestamp":1788463431000},"page":"101850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Autoimmune-associated thrombosis: mechanisms, population burden, and prevention strategies"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5993-4850","authenticated-orcid":false,"given":"Deepa J.","family":"Arachchillage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan V.","family":"Preece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Laffan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.lanepe.2026.101850_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11926-021-01038-2","article-title":"Epidemiology of antiphospholipid syndrome in the general population","volume":"23","author":"Dabit","year":"2022","journal-title":"Curr Rheumatol Rep"},{"issue":"SI","key":"10.1016\/j.lanepe.2026.101850_bib2","doi-asserted-by":"crossref","first-page":"SI72","DOI":"10.1093\/rheumatology\/kead618","article-title":"The impact of antiphospholipid antibodies\/antiphospholipid syndrome on systemic lupus erythematosus","volume":"63","author":"Venturelli","year":"2024","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101850_bib3","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1093\/rheumatology\/keac596","article-title":"Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events","volume":"62","author":"Farina","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101850_bib4","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","article-title":"Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021","volume":"5","author":"GBD 2021 Rheumatoid Arthritis Collaborators","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.lanepe.2026.101850_bib5","article-title":"Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management","volume":"380","author":"Knight","year":"2023","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101850_bib6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bjh.20216","article-title":"Anti-PF4 disorders: pathogenesis, diagnosis and treatment","volume":"207","author":"Preece","year":"2025","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101850_bib7","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/0961203309106832","article-title":"The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe","volume":"18","author":"Cervera","year":"2009","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101850_bib8","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1136\/ard.2008.093179","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients","volume":"68","author":"Cervera","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lanepe.2026.101850_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2026.101364","article-title":"Revisiting antiphospholipid syndrome: a thrombo-inflammatory disorder beyond clotting","volume":"76","author":"Ducker","year":"2026","journal-title":"Blood Rev"},{"key":"10.1016\/j.lanepe.2026.101850_bib10","article-title":"Inflammation and cardiovascular disease: from mechanisms to therapeutics","volume":"4","author":"Alfaddagh","year":"2020","journal-title":"Am J Prev Cardiol"},{"issue":"11","key":"10.1016\/j.lanepe.2026.101850_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103447","article-title":"Risk of venous thromboembolism in autoimmune diseases: a comprehensive review","volume":"22","author":"Menichelli","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101850_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.htct.2023.05.008","article-title":"Immunothrombosis and its underlying biological mechanisms","volume":"46","author":"De Nardi","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.lanepe.2026.101850_bib13","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fcvm.2024.1433858","article-title":"Editorial: inflammation, the link between venous and arterial thrombosis","volume":"11","author":"\u017digon","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.lanepe.2026.101850_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1361519","article-title":"Interaction of antiphospholipid antibodies with endothelial cells in antiphospholipid syndrome","volume":"15","author":"Feng","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.lanepe.2026.101850_bib15","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3389\/fimmu.2018.00969","article-title":"Cellular and molecular mechanisms of anti-phospholipid syndrome","volume":"9","author":"Radic","year":"2018","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101850_bib16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41419-020-02928-6","article-title":"Autoantibody-dependent amplification of inflammation in SLE","volume":"11","author":"Lou","year":"2020","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101850_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10238-024-01359-3","article-title":"The role of anti-citrullinated protein antibody in pathogenesis of RA","volume":"24","author":"Ma","year":"2024","journal-title":"Clin Exp Med"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101850_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/cei\/uxac090","article-title":"Cytokine production by human B cells: role in health and autoimmune disease","volume":"210","author":"de Gruijter","year":"2022","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101850_bib19","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1046\/j.1538-7836.2003.00261.x","article-title":"Inflammation and thrombosis","volume":"1","author":"Esmon","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101850_bib20","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/apa.70193","article-title":"Post-Viral Acquired Idiopathic Purpura Fulminans Caused by Anti-Protein S Antibodies","volume":"114","author":"Theron","year":"2025","journal-title":"Acta Paediatr"},{"issue":"11","key":"10.1016\/j.lanepe.2026.101850_bib21","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/jth.12722","article-title":"Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome","volume":"12","author":"Arachchillage","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.lanepe.2026.101850_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1791619","article-title":"Regulation of histones in thromboinflammation","volume":"17","author":"Mohiuddin","year":"2026","journal-title":"Front Immunol"},{"key":"10.1016\/j.lanepe.2026.101850_bib23","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2147\/VHRM.S519426","article-title":"Vascular endothelium in health and disease: structure, function, assessment and role in metabolic disorders","volume":"21","author":"Pluta","year":"2025","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.lanepe.2026.101850_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1267091","article-title":"The role of inflammation in autoimmune disease: a therapeutic target","volume":"14","author":"Xiang","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101850_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9070781","article-title":"Inflammatory mechanisms contributing to endothelial dysfunction","volume":"9","author":"Theofilis","year":"2021","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101850_bib26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/labinvest.3780446","article-title":"Leukocyte-endothelial cell interactions in the inflammatory response","volume":"82","author":"Muller","year":"2002","journal-title":"Lab Invest"},{"issue":"26","key":"10.1016\/j.lanepe.2026.101850_bib27","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1182\/blood-2017-04-780825","article-title":"Platelet interaction with activated endothelium: mechanistic insights from microfluidics","volume":"130","author":"Coenen","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101850_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102929","article-title":"Endothelial cell source dictates the expression and release of fibrinolytic markers in a proinflammatory environment","volume":"9","author":"Humphreys","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101850_bib29","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/CIRCRESAHA.116.309326","article-title":"Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis","volume":"120","author":"F\u00f6rstermann","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.lanepe.2026.101850_bib30","article-title":"Immunopathogenesis of accelerated atherosclerosis in systemic lupus erythematosus: from innate and adaptive dysregulation to clinical implications","volume":"17","author":"Cao","year":"2026","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101850_bib31","article-title":"Vascular endothelial cell injury: causes, molecular mechanisms, and treatments","volume":"6","author":"Xia","year":"2025","journal-title":"MedComm (2020)"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101850_bib32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00281-022-00929-5","article-title":"Diseases of blood vessels: immune system involvement in vasculitis and vasculopathy","volume":"44","author":"Grayson","year":"2022","journal-title":"Semin Immunopathol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101850_bib33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2147\/vhrm.2005.1.4.357","article-title":"Endothelial function in systemic lupus erythematosus: relationship to disease activity, cardiovascular risk factors, corticosteroid therapy, and coronary calcification","volume":"1","author":"Turner","year":"2005","journal-title":"Vasc Health Risk Manag"},{"issue":"Supplement_1","key":"10.1016\/j.lanepe.2026.101850_bib34","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-121113","article-title":"Links between complement activation and thrombosis","volume":"134","author":"Ruf","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.lanepe.2026.101850_bib35","series-title":"Molecular and Cellular Basis of Inflammation","first-page":"1","article-title":"Role of complement in endothelial cell activation","author":"Ward","year":"1999"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101850_bib36","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/jth.15082","article-title":"Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications","volume":"19","author":"Chaturvedi","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101850_bib37","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/hematology.2024000544","article-title":"Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease","volume":"2024","author":"Salter","year":"2024","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101850_bib38","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.thromres.2012.11.021","article-title":"Increased circulating red cell microparticles (RMP) and platelet microparticles (PMP) in immune thrombocytopenic purpura","volume":"131","author":"Sewify","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.lanepe.2026.101850_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109109","article-title":"The immune thrombocytopenia paradox: should we be concerned about thrombosis in ITP?","volume":"241","author":"Saldanha","year":"2024","journal-title":"Thromb Res"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101850_bib40","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3324\/haematol.2009.018390","article-title":"Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database","volume":"95","author":"Sarpatwari","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101850_bib41","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/j.2040-4603.2015.tb00649.x","article-title":"Platelets and their interactions with other immune cells","volume":"5","author":"Lam","year":"2015","journal-title":"Compr Physiol"},{"key":"10.1016\/j.lanepe.2026.101850_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100694","article-title":"Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: potential role of antiplatelet agents","volume":"45","author":"Lordan","year":"2021","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101850_bib43","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1055\/a-2087-0314","article-title":"Platelets and the lectin pathway of complement activation in patients with systemic lupus erythematosus or antiphospholipid syndrome","volume":"7","author":"Vils","year":"2023","journal-title":"TH Open"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101850_bib44","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3390\/jcm13030741","article-title":"Platelets and thrombotic antiphospholipid syndrome","volume":"13","author":"Tohidi-Esfahani","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101850_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2023000503","article-title":"Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond","volume":"2023","author":"Greinacher","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101850_bib46","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/jth.12905","article-title":"Human platelet IgG Fc receptor Fc\u03b3RIIA in immunity and thrombosis","volume":"13","author":"Arman","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.lanepe.2026.101850_bib47","first-page":"263","article-title":"Platelet Fc\u03b3RIIA receptor","volume":"vol. 1","author":"McKenzie","year":"2025"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101850_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23750","article-title":"Procoagulant platelets: generation, characteristics, and therapeutic target","volume":"35","author":"Chu","year":"2021","journal-title":"J Clin Lab Anal"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101850_bib49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41569-026-01250-6","article-title":"Procoagulant platelets: linking coagulation and thromboinflammation in cardiovascular disease","volume":"23","author":"Kaiser","year":"2026","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101850_bib50","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1038\/s41467-022-32946-1","article-title":"NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia","volume":"13","author":"Leung","year":"2022","journal-title":"Nat Commun"},{"issue":"25","key":"10.1016\/j.lanepe.2026.101850_bib51","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2021012277","article-title":"Antiplatelet drugs block platelet activation by VITT patient serum","volume":"138","author":"Smith","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.lanepe.2026.101850_bib52","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/978-1-4939-9424-3_31","article-title":"Neutrophil extracellular traps","volume":"1982","author":"Rada","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101850_bib53","first-page":"1332","article-title":"Immune thrombosis: exploring the significance of immune complexes and NETosis","volume":"12","author":"Perdomo","year":"2023","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.lanepe.2026.101850_bib54","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.3389\/fimmu.2019.02734","article-title":"Neutrophils-important communicators in systemic lupus erythematosus and antiphospholipid syndrome","volume":"10","author":"Wirestam","year":"2019","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.lanepe.2026.101850_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713581","article-title":"The role of neutrophil extracellular traps (NETs) in the pathogenesis of systemic lupus erythematosus and antiphospholipid syndrome","volume":"24","author":"Reshetnyak","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"18","key":"10.1016\/j.lanepe.2026.101850_bib56","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood-2013-10-463646","article-title":"Thrombosis: tangled up in NETs","volume":"123","author":"Martinod","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101850_bib57","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s42269-024-01174-6","article-title":"Oxidative stress and inflammation: elucidating mechanisms of smoking-attributable pathology for therapeutic targeting","volume":"48","author":"Addissouky","year":"2024","journal-title":"Bull Natl Res Cent"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101850_bib58","doi-asserted-by":"crossref","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"issue":"21","key":"10.1016\/j.lanepe.2026.101850_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262110292","article-title":"The interplay between obesity and venous thromboembolism: from molecular aspects to clinical issue","volume":"26","author":"Zawadzka","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.lanepe.2026.101850_bib60","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/asheducation-2015.1.53","article-title":"The antiphospholipid syndrome: still an enigma","volume":"2015","author":"Chaturvedi","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101850_bib61","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/bjh.19635","article-title":"Guidelines on the investigation and management of antiphospholipid syndrome","volume":"205","author":"Arachchillage","year":"2024","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101850_bib62","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101850_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002534","article-title":"Triple positive profile in antiphospholipid syndrome: prognosis, relapse and management from a retrospective multicentre study","volume":"9","author":"Laurent","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.lanepe.2026.101850_bib64","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fmed.2017.00262","article-title":"Novel insights in systemic lupus erythematosus and atherosclerosis","volume":"4","author":"Teixeira","year":"2017","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101850_bib65","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1002\/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I","article-title":"Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus","volume":"44","author":"Esdaile","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101850_bib66","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjh.16431","article-title":"What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome?","volume":"189","author":"Arachchillage","year":"2020","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.lanepe.2026.101850_bib67","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101850_bib68","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101850_bib69","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.lanepe.2026.101850_bib70","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.jtha.2024.03.027","article-title":"Dilemmas in the diagnosis and management of antiphospholipid syndrome","volume":"22","author":"Manning","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101850_bib71","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.mcna.2020.09.010","article-title":"Managing cardiovascular risk in patients with rheumatic disease","volume":"105","author":"Ferguson","year":"2021","journal-title":"Med Clin North Am"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101850_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021331","article-title":"Hydroxychloroquine as an immunomodulatory and antithrombotic treatment in antiphospholipid syndrome","volume":"24","author":"Arachchillage","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.lanepe.2026.101850_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.950465","article-title":"Immunomodulatory actions of vitamin D in various immune-related disorders: a comprehensive review","volume":"14","author":"Ghaseminejad-Raeini","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.lanepe.2026.101850_bib74","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.thromres.2015.11.033","article-title":"The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs","volume":"137","author":"Grosse","year":"2016","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101850_bib75","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/2396987319883160","article-title":"Economic burden of stroke across Europe: a population-based cost analysis","volume":"5","author":"Luengo-Fernandez","year":"2020","journal-title":"Eur Stroke J"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101850_bib76","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41577-023-00904-7","article-title":"The immunology of long COVID","volume":"23","author":"Altmann","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101850_bib77","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41577-022-00762-9","article-title":"Understanding COVID-19-associated coagulopathy","volume":"22","author":"Conway","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101850_bib78","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMoa2514824","article-title":"Adenoviral inciting antigen and somatic hypermutation in VITT","volume":"394","author":"Wang","year":"2026","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101850_bib79","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMoa2415930","article-title":"VITT-like monoclonal gammopathy of thrombotic significance","volume":"392","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101850_bib80","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjh.19180","article-title":"Diagnosis and management of heparin-induced thrombocytopenia: third edition","volume":"204","author":"Arachchillage","year":"2024","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101850_bib81","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101850_bib82","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40259-019-00400-2","article-title":"Bispecific antibodies for autoimmune and inflammatory diseases: clinical progress to date","volume":"34","author":"Zhao","year":"2020","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101850_bib83","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1515\/rir-2024-0029","article-title":"Therapeutic potential of CD20\/CD3 bispecific antibodies in the treatment of autoimmune diseases","volume":"5","author":"Huang","year":"2024","journal-title":"Rheumatol Immunol Res"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:17:48Z","timestamp":1793632668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226002620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":83,"alternative-id":["S2666776226002620"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101850","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune-associated thrombosis: mechanisms, population burden, and prevention strategies","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101850","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101850"}}